lodenafil carbonate: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 135431100 |
| CHEMBL ID | 4297515 |
| SCHEMBL ID | 5008159 |
| SCHEMBL ID | 18074278 |
| MeSH ID | M0525690 |
| Synonym |
|---|
| 4-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-1-piperazineethanol carbonate ester |
| lodenafil carbonate |
| cris-031 |
| helleva |
| 29x84f932d , |
| lodenafil carbonate [inn] |
| 398507-55-6 |
| bis-(2-(4-(4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1h-pyrazolo(4,3-d)pyrimidin-5-yl)-benzenesulfonyl)piperazin-1-yl)-ethyl)carbonate |
| unii-29x84f932d |
| 7h-pyrazolo(4,3-d)pyrimidin-7-one, 5,5'-(carbonylbis(oxy-2,1-ethanediyl-4,1-piperazinediylsulfonyl(6-ethoxy-3,1-phenylene)))bis(1,6-dihydro-1-methyl-3-propyl- |
| lodenafil carbonate [who-dd] |
| 1-piperazineethanol, 4-((3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-, carbonate (2:1) (ester) |
| bis(2-(4-(4-ethoxy-3-(1-methyl-7-oxo-3-propyl-4,7-dihydro-1h-pyrazolo(4,3-d)pyrimidin-5-yl)phenylsulfonyl)piperazin-1-yl)ethyl) carbonate |
| SCHEMBL5008159 |
| bis[2-[4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]ethyl] carbonate |
| DTXSID70192906 |
| SCHEMBL18074278 |
| DB11927 |
| HY-108045 |
| bis[2-[4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6h-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]ethyl] carbonate |
| CS-0027223 |
| 7h-pyrazolo[4,3-d]pyrimidin-7-one, 5,5'-[carbonylbis[oxy-2,1-ethanediyl-4,1-piperazinediylsulfonyl(6-ethoxy-3,1-phenylene)]]bis[1,6-dihydro-1-methyl-3-propyl-; 1-piperazineethanol, 4-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazolo[4,3-d]pyrimidin-5-y |
| CHEMBL4297515 |
| MS-31886 |
| YQA50755 |
| lodenafilcarbonate |
| AKOS040755757 |
Lodenafil carbonate is a new phosphodiesterase Type 5 (PDE5) inhibitor used in treatment of erectile dysfunction.
Lodenafil carbonate bioavailability was increased in 74% when drug intake was associated with alcohol.
| Excerpt | Reference |
|---|---|
| " Lodenafil carbonate bioavailability was increased in 74% when drug intake was associated with alcohol." | ( [Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, with and without alcohol consumption]. Afiune, JB; Lucio, LA; Massud Filho, J; Santos, PF; Silva, AC; Toffoletto, O; Tufik, S, 2010) |
| " The association of lodenafil carbonate and alcohol affected its pharmacokinetic properties, increasing the bioavailability of the drug." | ( [Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, with and without alcohol consumption]. Afiune, JB; Lucio, LA; Massud Filho, J; Santos, PF; Silva, AC; Toffoletto, O; Tufik, S, 2010) |
| Excerpt | Reference |
|---|---|
| " This study showed that the dosage of 80 mg of LC was significantly more efficacious than placebo and well tolerated." | ( Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. Claro, JF; de Góes, PM; Glina, S; Gomatzky, C; Júnior, AN; Pagani, E; Toscano, I, 2009) |
| "To assess persistence/adherence rates of phosphodiesterase type-5 inhibitor (PDE5I) on-demand dosing in Latin American men with erectile dysfunction (ED), and explore patient characteristics and treatment factors that may be predictive for PDE5I persistence and adherence." | ( A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction. Borregales, L; Cairoli, C; Reyes, LA; Rubio-Aurioles, E; Sorsaburu, S, 2013) |
| "Men from Brazil, Mexico, and Venezuela with ED who were naïve to PDE5Is were prescribed sildenafil, tadalafil, vardenafil, or lodenafil on-demand dosing and asked to provide information about PDE5I use at baseline and at 1, 3, and 6 months." | ( A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction. Borregales, L; Cairoli, C; Reyes, LA; Rubio-Aurioles, E; Sorsaburu, S, 2013) |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 6 (50.00%) | 5.53% |
| Reviews | 1 (8.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 1 (8.33%) | 0.25% |
| Other | 4 (33.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||